Phase I study of neocarzinostatin in children with cancer.
Twenty-three children with advanced cancer refractory to conventional therapy received weekly iv doses of neocarzinostatin for 5 weeks. Doses were escalated from 500 to 6750 units/m2/week. Four types of toxic manifestations occurred: acute reactions consisting of shaking chills with or without fever and cyanosis (rigor), hypersensitivity, vomiting, and marrow depression. Evidence of oncolytic activity was limited to patients with acute leukemia in whom phase II trials at doses between 3000 and 4500 units/m2 appear warranted.
D000293:Adolescent; D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology*; D001853:Bone Marrow / Q000187:drug effects; D002648:Child; D002675:Child, Preschool; D004341:Drug Evaluation; D004342:Drug Hypersensitivity; D006801:Humans; D007223:Infant; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy*; D012075:Remission, Spontaneous; D012768:Shivering / Q000187:drug effects; D014839:Vomiting / Q000139:chemically induced; D009353:Zinostatin / Q000494:pharmacology* / Q000633:toxicity
D000903:Antibiotics, Antineoplastic; D009353:Zinostatin